Bioservo: Q4’22, Initial take – Focus on 2023 - Redeye

Redeye saw sales lower than our expectations in the Q4 report partly due to the delays for Carbonhand in the quarter. The cost was also higher as the company has increased its cost to push for the commercialization of Carbonhand going into 2023e. The final results of the iHand study and the MDR are strong points going into 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/882153/bioservo-q422-initial-take-focus-on-2023?utm_source=finwire&utm_medium=RSS